Bronchial salivary gland–type intraductal carcinoma with KIAA1217::RET gene fusion composed of intercalated and oncocytic components

Song, Lin; Cheng, Xiankui; Yang, Zhen; Ji, Xiangyu; Zhou, Xiaoli; Cheng, Hongxia; Lin, Dongliang

doi:10.1007/s00428-022-03456-8

Cited by 2 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…196 Both pulmonary intraductal carcinomas had p63positive myoepithelial cells. 27,28 In one case the tumour cells showed immunoreactivity for AR, in keeping with an apocrine phenotype, and had immunoreactivity for TTF-1 (clone not specified). 27 The other intraductal carcinoma was negative for AR but positive for S100, SOX10, and mammaglobin, in keeping with an intercalated duct/oncocytic phenotype.…”

Section: S a L I V A R Y D U C T C A R C I N O M Amentioning

confidence: 99%

“…Two such cases have been reported primary in the lung. 27,28 Both pulmonary intraductal carcinomas were identified in adults (63 and 67 years old) and formed endobronchial masses. 27,28 This is another salivary gland-type tumour that is comprised of two components, an epithelial and a myoepithelial component.…”

Section: S a L I V A R Y D U C T C A R C I N O M Amentioning

confidence: 99%

“…27,28 Both pulmonary intraductal carcinomas were identified in adults (63 and 67 years old) and formed endobronchial masses. 27,28 This is another salivary gland-type tumour that is comprised of two components, an epithelial and a myoepithelial component. The epithelial component is composed of rounded nests of neoplastic cells arranged in solid, cribriform, or micropapillary patterns.…”

Section: S a L I V A R Y D U C T C A R C I N O M Amentioning

confidence: 99%

“…27 The other intraductal carcinoma was negative for AR but positive for S100, SOX10, and mammaglobin, in keeping with an intercalated duct/oncocytic phenotype. 27,28 RET translocations are present in the majority of intraductal carcinomas of the head and neck, 196 but also occur in approximately 1% of NSCLC. 197 One of the pulmonary intraductal carcinomas harboured a KIAA1217::RET fusion, 28 which has also been reported in an acinar predominant pulmonary adenocarcinoma.…”

Section: S a L I V A R Y D U C T C A R C I N O M Amentioning

confidence: 99%

“…The most common types of pulmonary salivary gland-type carcinoma include mucoepidermoid carcinoma (MEC), adenoid cystic carcinoma (AdCC), and epithelial-myoepithelial carcinoma (EMC). 6,8,[10][11][12][13] Case reports and series have also described hyalinizing clear cell carcinoma (HCCC), 4,14,15 acinic cell carcinoma (AciCC), [16][17][18][19] secretory carcinoma, [20][21][22][23] salivary duct carcinoma, [24][25][26] intraductal carcinoma, 27,28 and polymorphous adenocarcinoma [29][30][31][32][33] occurring as primary lung tumours. Benign salivary gland-type tumours reported in the lung include myoepithelial tumours and pleomorphic adenomas.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Recent developments in the pathology of primary pulmonary salivary gland‐type tumours

Naso,

Roden

2023

Histopathology

View full text Add to dashboard Cite

Primary pulmonary salivary gland‐type tumours are rare neoplasms that are thought to arise from seromucinous glands that are located in the submucosa of large airways. These neoplasms have clinical and pathologic features that are distinct from other pulmonary neoplasms. The majority of primary pulmonary salivary gland‐type tumours are malignant, with the most common entities being mucoepidermoid carcinoma, adenoid cystic carcinoma, and epithelial‐myoepithelial carcinoma. Less commonly seen are myoepithelial carcinoma, hyalinizing clear cell carcinoma, acinic cell carcinoma, secretory carcinoma, salivary duct carcinoma, intraductal carcinoma, and polymorphous adenocarcinoma. Benign salivary gland‐type tumours of the lung include pleomorphic adenoma and sialadenoma papilliferum. Morphologic, immunophenotypic, and molecular features of these neoplasms are largely similar to salivary gland tumours elsewhere, and therefore the exclusion of metastatic disease requires clinical and radiologic correlation. However, the differential diagnostic considerations are different in the lung. The distinction of salivary gland‐type tumours from their histologic mimics is important for both prognostication and treatment decisions. Overall, salivary gland type‐tumours tend to have a more favourable outcome than other pulmonary carcinomas, although high‐grade variants exist for many of these tumour types. Recent advances in our understanding of the spectrum of salivary gland‐type tumours reported in the lung and their diversity of molecular and immunohistochemical features have helped to refine the classification of these tumours and have highlighted a few differences between salivary gland‐type tumours of the lung and those primary to other sites.

show abstract

Section: S a L I V A R Y D U C T C A R C I N O M Amentioning

confidence: 99%

Section: S a L I V A R Y D U C T C A R C I N O M Amentioning

confidence: 99%

Section: S a L I V A R Y D U C T C A R C I N O M Amentioning

confidence: 99%

Section: S a L I V A R Y D U C T C A R C I N O M Amentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Recent developments in the pathology of primary pulmonary salivary gland‐type tumours

Naso,

Roden

2023

Histopathology

View full text Add to dashboard Cite

show abstract

Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification

Zhou,

Wu,

Zhang

et al. 2023

PeerJ

View full text Add to dashboard Cite

Objective Thyroid cancer is the third most prevalent cancer among females. Genetic testing based on next-generation sequencing may provide an auxiliary diagnosis to reduce cytologically diagnostic uncertainty. However, commercial multigene tests are not widely available and are not well-tested in the Chinese population. Methods In this study, we designed a multigene testing panel and evaluated its performance in 529 cytologically indeterminate thyroid nodules (Bethesda III, IV and V). The molecular data of the DNA mutations and RNA fusions of fine needle aspiration samples were reviewed in conjunction with a clinical diagnosis, pathological reports, and definitive surgery for retrospective analysis. Then, the molecular risk stratification was investigated for its accuracy in malignant risk prediction. Results The overall combined consistency revealed substantial agreement (Kappa = 0.726) with the sensitivity, specificity, positive predictive value, and negative predictive values of 97.80%, 82.14%, 98.99%, and 67.65%, respectively. The most common aberration was BRAFV600E (82.59%), followed by NRAS mutants (4.07%), RET fusions (3.70%), and KRAS mutants (3.15%). Two cases (0.44%) were categorized into a high-risk group, 426 cases (94.67%) were categorized into a BRAF-like group with totally histopathologic papillary patterned tumors, and 22 cases (4.89%) were categorized into a RAS-like group with 14 papillary and eight follicular patterned tumors when the cohort concurrent aberrations were excluded. Potentially aggressive features may be related to concurrent molecular alterations of BRAFV600E with TERTQ302R, and AKT1L52R, NRASG12C, NRASQ61R, and CCDC6-RET fusions. Conclusions This study provided a multigene panel for identifying benign nodules from cytologically indeterminate thyroid nodules to avoid unnecessary surgery. We provide further evidence for using molecular risk stratification as a promising predictor of disease outcomes. The results of this study may be limited by the extremely high prevalence of cancer in the cohort for clinical reference.

show abstract

Bronchial salivary gland–type intraductal carcinoma with KIAA1217::RET gene fusion composed of intercalated and oncocytic components

Cited by 2 publications

References 25 publications

Recent developments in the pathology of primary pulmonary salivary gland‐type tumours

Recent developments in the pathology of primary pulmonary salivary gland‐type tumours

Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification

Contact Info

Product

Resources

About